87 related articles for article (PubMed ID: 25902338)
1. Characterization of the Ala62Pro polymorphic variant of human cytochrome P450 1A1 using recombinant protein expression.
Lee SH; Kang S; Dong MS; Park JD; Park J; Rhee S; Ryu DY
Toxicol Appl Pharmacol; 2015 Jun; 285(3):159-69. PubMed ID: 25902338
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the Gly45Asp variant of human cytochrome P450 1A1 using recombinant expression.
Lee SH; Yu HJ; Lee S; Ryu DY
Toxicol Lett; 2015 Dec; 239(2):81-9. PubMed ID: 26367467
[TBL] [Abstract][Full Text] [Related]
3. Biochemical characterization of variants of canine CYP1A1 using heterologous expression.
Yu HJ; Lee SH; Lee S; Choi YJ; Oh D; Nam KH; Yun Y; Ryu DY
J Vet Med Sci; 2017 Aug; 79(8):1327-1334. PubMed ID: 28652520
[TBL] [Abstract][Full Text] [Related]
4. The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism.
Liu J; Ericksen SS; Sivaneri M; Besspiata D; Fisher CW; Szklarz GD
Arch Biochem Biophys; 2004 Apr; 424(1):33-43. PubMed ID: 15019834
[TBL] [Abstract][Full Text] [Related]
5. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility.
Persson I; Johansson I; Ingelman-Sundberg M
Biochem Biophys Res Commun; 1997 Feb; 231(1):227-30. PubMed ID: 9070254
[TBL] [Abstract][Full Text] [Related]
6. Enzymatic characterization of in vitro-expressed Baikal seal cytochrome P450 (CYP) 1A1, 1A2, and 1B1: implication of low metabolic potential of CYP1A2 uniquely evolved in aquatic mammals.
Iwata H; Yamaguchi K; Takeshita Y; Kubota A; Hirakawa S; Isobe T; Hirano M; Kim EY
Aquat Toxicol; 2015 May; 162():138-151. PubMed ID: 25814058
[TBL] [Abstract][Full Text] [Related]
7. Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity.
Schwarz D; Kisselev P; Schunck WH; Chernogolov A; Boidol W; Cascorbi I; Roots I
Pharmacogenetics; 2000 Aug; 10(6):519-30. PubMed ID: 10975606
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling of cytochrome P450 1A1: enzyme-substrate interactions and substrate binding affinities.
Szklarz GD; Paulsen MD
J Biomol Struct Dyn; 2002 Oct; 20(2):155-62. PubMed ID: 12354067
[TBL] [Abstract][Full Text] [Related]
9. Characterization of substrate binding to cytochrome P450 1A1 using molecular modeling and kinetic analyses: case of residue 382.
Liu J; Ericksen SS; Besspiata D; Fisher CW; Szklarz GD
Drug Metab Dispos; 2003 Apr; 31(4):412-20. PubMed ID: 12642467
[TBL] [Abstract][Full Text] [Related]
10. The use of macroporous microcarriers for the large-scale growth of V79 cells genetically designed to express single human cytochrome P450 isoenzymes and for the characterization of the expressed cytochrome P450.
Onderwater RC; Goeptar AR; Levering PR; Vos RM; Konings PN; Doehmer J; Commandeur JN; Vermeulen NP
Protein Expr Purif; 1996 Dec; 8(4):439-46. PubMed ID: 8954891
[TBL] [Abstract][Full Text] [Related]
11. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1.
Shimada T; Gillam EM; Sutter TR; Strickland PT; Guengerich FP; Yamazaki H
Drug Metab Dispos; 1997 May; 25(5):617-22. PubMed ID: 9152602
[TBL] [Abstract][Full Text] [Related]
12. Oxidation of carcinogenic benzo[a]pyrene by human and rat cytochrome P450 1A1 and its influencing by cytochrome b5 - a comparative study.
Indra R; Moserova M; Sulc M; Frei E; Stiborova M
Neuro Endocrinol Lett; 2013; 34 Suppl 2():55-63. PubMed ID: 24362093
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity.
Hanna IH; Dawling S; Roodi N; Guengerich FP; Parl FF
Cancer Res; 2000 Jul; 60(13):3440-4. PubMed ID: 10910054
[TBL] [Abstract][Full Text] [Related]
14. cDNA-directed expression of a functional zebrafish CYP1A in yeast.
Chung WG; Sen A; Wang-Buhler JL; Yang YH; Lopez N; Merrill GF; Miranda CL; Hu CH; Buhler DR
Aquat Toxicol; 2004 Nov; 70(2):111-21. PubMed ID: 15522429
[TBL] [Abstract][Full Text] [Related]
15. Functional characterization of human and cynomolgus monkey cytochrome P450 2E1 enzymes.
Hanioka N; Yamamoto M; Iwabu H; Jinno H; Tanaka-Kagawa T; Naito S; Shimizu T; Masuda K; Katsu T; Narimatsu S
Life Sci; 2007 Oct; 81(19-20):1436-45. PubMed ID: 17935737
[TBL] [Abstract][Full Text] [Related]
16. Targeting of active human cytochrome P4501A1 (CYP1A1) to the periplasmic space of Escherichia coli.
Kaderbhai MA; Ugochukwu CC; Lamb DC; Kelly SL
Biochem Biophys Res Commun; 2000 Dec; 279(3):803-7. PubMed ID: 11162432
[TBL] [Abstract][Full Text] [Related]
17. Modulation of human cytochrome P450 1A1-mediated oxidation of benzo[a]pyrene by NADPH:cytochrome P450 oxidoreductase and cytochrome b5.
Indra R; Moserova M; Kroftova N; Sulc M; Martinkova M; Adam V; Eckschlager T; Kizek R; Arlt VM; Stiborova M
Neuro Endocrinol Lett; 2014; 35 Suppl 2():105-13. PubMed ID: 25638374
[TBL] [Abstract][Full Text] [Related]
18. Human lung microsomal cytochrome P4501A1 (CYP1A1) activities: impact of smoking status and CYP1A1, aryl hydrocarbon receptor, and glutathione S-transferase M1 genetic polymorphisms.
Smith GB; Harper PA; Wong JM; Lam MS; Reid KR; Petsikas D; Massey TE
Cancer Epidemiol Biomarkers Prev; 2001 Aug; 10(8):839-53. PubMed ID: 11489750
[TBL] [Abstract][Full Text] [Related]
19. Comparative homology modeling of human cytochrome P4501A1 (CYP1A1) and confirmation of residues involved in 7-ethoxyresorufin O-deethylation by site-directed mutagenesis and enzyme kinetic analysis.
Lewis BC; Mackenzie PI; Miners JO
Arch Biochem Biophys; 2007 Dec; 468(1):58-69. PubMed ID: 17959138
[TBL] [Abstract][Full Text] [Related]
20. Expression of modified human cytochrome P450 1A1 in Escherichia coli: effects of 5' substitution, stabilization, purification, spectral characterization, and catalytic properties.
Guo Z; Gillam EM; Ohmori S; Tukey RH; Guengerich FP
Arch Biochem Biophys; 1994 Aug; 312(2):436-46. PubMed ID: 8037457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
